ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer - UroToday
Dr. Himisha Beltran discussed DLL3 as a therapeutic target for neuroendocrine prostate cancer at the 2024 ESMO Congress. DLL3 expression increases in castrate-resistant prostate cancer and is crucial for maintaining a neuroendocrine phenotype. Despite early promising results with DLL3-targeted therapies like Rova-T, efficacy was limited and toxicity high. Ongoing DLL3-targeted therapies include T cell engagers, ADCs, radionuclides, and CAR-T. Tarlatamab, a DLL3-targeted bi-specific T cell engager, showed limited efficacy in neuroendocrine prostate cancer. MK-6070, another DLL3-targeted T cell engager, demonstrated strong anti-tumor activity in neuroendocrine prostate cancer models. Future PET imaging with <sup>89</sup>Zr-SC16 may aid in patient selection and resistance pattern understanding.
Reference News
Dr. Himisha Beltran discussed DLL3 as a therapeutic target for neuroendocrine prostate cancer at the 2024 ESMO Congress. DLL3 expression increases in castrate-resistant prostate cancer and is crucial for maintaining a neuroendocrine phenotype. Despite early promising results with DLL3-targeted therapies like Rova-T, efficacy was limited and toxicity high. Ongoing DLL3-targeted therapies include T cell engagers, ADCs, radionuclides, and CAR-T. Tarlatamab, a DLL3-targeted bi-specific T cell engager, showed limited efficacy in neuroendocrine prostate cancer. MK-6070, another DLL3-targeted T cell engager, demonstrated strong anti-tumor activity in neuroendocrine prostate cancer models. Future PET imaging with <sup>89</sup>Zr-SC16 may aid in patient selection and resistance pattern understanding.